Md Abdul Hye Khan, Ph.D
University of Arkansas for Medical Sciences, University of Missouri, Universiti Sains Malaysia, University of Rajshahi, University of Tennessee Health Science Center
0000-0001-5940-9300
About
Dr. Md Abdul Hye Khan is an accomplished preclinical drug development researcher and educator with over 15 years of experience in biomedical education and research. He is a recognized expert in integrative physiology, pharmacology, and in vivo preclinical and translational research focused on cardiovascular, renal, and anti-fibrotic drug development. Dr. Khan also has a robust background in clinical research, having served as a Research Fellow in a large hospital setting, and has industry experience as a Research Scientist in a biopharmaceutical company. His expertise also spans epidemiological research, health data collection, and data curation. He has authored or co-authored 81 peer-reviewed research and review articles, 2 book chapters, and over 50 scientific abstracts. His scholarly impact is reflected in a Google Scholar H-index of 29. Dr. Khan has mentored 17 undergraduate students, 6 medical students, 2 postdoctoral fellows, and 2 graduate students, demonstrating a strong commitment to academic mentorship and training. His research contributions have been recognized with multiple awards, fellowships, and grants from prestigious organizations including the American Heart Association, Pharmaceutical Foundation of America, American Physiological Society, and the American Society for Pharmacology & Experimental Therapeutics. He holds three U.S. patents for novel therapeutic molecules targeting cardiovascular, cardiometabolic, and renal diseases. Dr. Khan serves on the editorial boards of several leading journals, including BMC Nephrology and Frontiers in Pharmacology. He has also held leadership roles within professional societies, including serving as a Councillor for the Great Lakes Chapter of ASPET and as a member of the Conference and Meeting Committee of the Missouri Physiological Society.
For publication list in PubMed please see
https://www.ncbi.nlm.nih.gov/sites/myncbi/1pc5As9FYqzkg/bibliography/51155047/public/?sort=date&direction=descending
Employment
-
University of Arkansas for Medical Sciences Associate Staff Scientist2024 - Present
-
University of Missouri Assistant Professor2023 - 2024
-
University of Tennessee Health Science Center Instructor2022 - 2023
-
Medical College of Wisconsin Assistant Professor2014 - 2021
Education
-
Universiti Sains Malaysia
-
University of Rajshahi
Projects & Funding
Projects & funding information is unavailable.
Publications (76)
- Renoprotective approaches against anthracycline nephrotoxicity. Save
- Renal hemodynamics underlie hepatorenal physiology in bile duct-ligated rats Save
- Dual acting inhibitor of soluble epoxide hydrolase and Cyclooxygenase-2, attenuates glomerular injury in renal hypoplasia mice. Save
- Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral-obstructed mice. Save
- Editorial: Debates in experimental pharmacology and drug discovery 2023: innovative approaches to chronic kidney disease drug discovery, identification of targets and safety assessment. Save
- EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage. Save
- Polystyrene microplastics cause reproductive toxicity in male mice. Save
- A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice. Save
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences. Save
- Dual soluble epoxide hydrolase inhibitor - farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis. Save